Group One Trading’s Neurocrine Biosciences NBIX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-3,000
Closed -$425K 8350
2025
Q4
$425K Buy
3,000
+1,300
+76% +$188K ﹤0.01% 3678
2025
Q3
$239K Sell
1,700
-3,400
-67% -$461K ﹤0.01% 4490
2025
Q2
$641K Sell
5,100
-15,800
-76% -$1.81M ﹤0.01% 3179
2025
Q1
$2.31M Buy
20,900
+15,500
+287% +$1.96M 0.01% 1694
2024
Q4
$737K Sell
5,400
-2,600
-33% -$322K ﹤0.01% 2850
2024
Q3
$922K Sell
8,000
-600
-7% -$82.3K ﹤0.01% 2369
2024
Q2
$1.18M Sell
8,600
-34,500
-80% -$4.73M ﹤0.01% 1854
2024
Q1
$5.94M Buy
43,100
+20,800
+93% +$2.84M 0.02% 726
2023
Q4
$2.94M Sell
22,300
-13,600
-38% -$1.57M 0.01% 1541
2023
Q3
$4.04M Buy
35,900
+4,600
+15% +$484K 0.01% 1080
2023
Q2
$2.95M Buy
31,300
+3,000
+11% +$293K 0.01% 1375
2023
Q1
$2.86M Sell
28,300
-71,400
-72% -$7.43M 0.01% 1235
2022
Q4
$11.9M Buy
99,700
+78,000
+359% +$9.14M 0.03% 635
2022
Q3
$2.31M Sell
21,700
-15,200
-41% -$1.54M ﹤0.01% 1788
2022
Q2
$3.6M Buy
36,900
+7,700
+26% +$711K 0.01% 1550
2022
Q1
$2.74M Buy
29,200
+700
+2% +$59.3K ﹤0.01% 2086
2021
Q4
$2.43M Buy
28,500
+16,800
+144% +$1.55M ﹤0.01% 2383
2021
Q3
$1.12M Sell
11,700
-19,400
-62% -$1.83M ﹤0.01% 3286
2021
Q2
$3.03M Sell
31,100
-19,500
-39% -$1.87M ﹤0.01% 2214
2021
Q1
$4.92M Buy
50,600
+19,300
+62% +$2.02M 0.01% 1527
2020
Q4
$3M Buy
31,300
+17,400
+125% +$1.68M 0.01% 1701
2020
Q3
$1.34M Buy
13,900
+8,800
+173% +$1.02M ﹤0.01% 1929
2020
Q2
$622K Sell
5,100
-13,500
-73% -$1.49M ﹤0.01% 2452
2020
Q1
$1.61M Sell
18,600
-19,700
-51% -$1.93M 0.01% 1185
2019
Q4
$4.12M Buy
38,300
+31,300
+447% +$3.28M 0.03% 793
2019
Q3
$631K Buy
7,000
+3,200
+84% +$299K 0.01% 2133
2019
Q2
$321K Sell
3,800
-4,800
-56% -$394K ﹤0.01% 2521
2019
Q1
$758K Sell
8,600
-3,900
-31% -$326K 0.01% 1612
2018
Q4
$893K Buy
12,500
+11,300
+942% +$1.08M 0.01% 1588
2018
Q3
$148K Sell
1,200
-61,300
-98% -$6.96M ﹤0.01% 3234
2018
Q2
$6.14M Buy
62,500
+34,200
+121% +$3.06M 0.05% 443
2018
Q1
$2.35M Buy
28,300
+8,300
+42% +$701K 0.02% 905
2017
Q4
$1.55M Buy
20,000
+18,800
+1,567% +$1.28M 0.01% 1356
2017
Q3
$74K Sell
1,200
-31,700
-96% -$1.67M ﹤0.01% 3415
2017
Q2
$1.51M Buy
32,900
+10,500
+47% +$509K 0.02% 1146
2017
Q1
$970K Buy
22,400
+3,300
+17% +$141K 0.01% 1353
2016
Q4
$739K Sell
19,100
-118,000
-86% -$5.34M 0.01% 1519
2016
Q3
$6.94M Sell
137,100
-25,400
-16% -$1.26M 0.08% 287
2016
Q2
$7.39M Buy
162,500
+132,800
+447% +$6.11M 0.09% 248
2016
Q1
$1.18M Sell
29,700
-40,600
-58% -$1.61M 0.02% 1070
2015
Q4
$3.98M Sell
70,300
-13,100
-16% -$666K 0.05% 469
2015
Q3
$3.32M Buy
83,400
+25,500
+44% +$1.23M 0.05% 524
2015
Q2
$2.77M Sell
57,900
-11,000
-16% -$466K 0.04% 566
2015
Q1
$2.74M Sell
68,900
-29,400
-30% -$1.05M 0.04% 489
2014
Q4
$2.2M Buy
98,300
+54,400
+124% +$1.03M 0.03% 601
2014
Q3
$688K Sell
43,900
-38,400
-47% -$574K 0.01% 1370
2014
Q2
$1.22M Buy
82,300
+44,900
+120% +$634K 0.02% 1000
2014
Q1
$602K Buy
37,400
+2,100
+6% +$35.9K 0.01% 1500
2013
Q4
$330K Sell
35,300
-16,700
-32% -$163K 0.01% 1991
2013
Q3
$589K Sell
52,000
-16,700
-24% -$230K 0.01% 1471
2013
Q2
$919K Buy
+68,700
New +$844K 0.02% 881

Other funds holding NBIX

Group One Trading's NBIX Position: Q1 2026 in Review

Group One Trading reduced its Neurocrine Biosciences (NBIX) stake by 24% in Q1 2026, selling an estimated $41.9K and leaving 1,014 shares worth $134K. The position accounts for ﹤0.01% of the portfolio, ranked #4463.

Group One Trading first reported a position in NBIX in Q2 2013 and has held it in 26 quarters since. The position peaked at $4.83M in Q1 2022. 694 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

  • Group One Trading held 1,014 shares of Neurocrine Biosciences worth $134K as of Q1 2026.
  • Group One Trading sold 316 Neurocrine Biosciences shares in Q1 2026, an estimated $41.9K.
  • Neurocrine Biosciences made up ﹤0.01% of Group One Trading's portfolio in Q1 2026, its #4463 holding.
  • Group One Trading first reported a position in Neurocrine Biosciences in Q2 2013 and has held it in 26 quarters since.
  • Group One Trading's Neurocrine Biosciences position peaked at $4.83M in Q1 2022.
  • 694 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on Group One Trading's 13F filing for Q1 2026, filed 13 May 2026.